A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102

Docetaxel and vinorelbine have demonstrated Single-agent activity in breast cancer. Preclinical studies suggest potential synergy between these antitubulin chemotherapy agents. This study evaluates these drugs in combination in metastatic breast cancer. Taxane-naive patients with HER-2 negative, sta...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gralow, Julie R., Barlow, William E., Lew, Danika, Dammann, Kim, Somlo, George, Rinn, Kristine J., Vogel, Stanley J., Wong, Lucas, Livingston, Robert B., Hortobagyi, Gabriel N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2013
Témata:
Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889983/
https://ncbi.nlm.nih.gov/pubmed/24352574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2797-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky